1Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on Prognosis Studies in SLE [J]. Arthritis Rheum, 1992,35(6):630-640.
3Wandl UB, Nagel-Hiemke M, May D, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative dimrders [J]. Clin Immunol Immunopathol, 1992,68(1):70-74.
4Ozmen L, Roman D, Fountoulakis M, et al. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis[J]. Eur J Immunol, 1995,25(1):6-12.
5Balomenos D, Rumold R, Theofilopoulos AN, et al. Interferongamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice [J]. J Clin Invest, 1998,101(2):364-371.
6Lawson BR, Prud' homme GJ, Chang Y, et al. Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc [J]. J Clin Invest, 2000,106(2):207-215.
7Akahoshi M, Nakashima H, Tanaka Y, et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus [J].Arthritis Rheum, 1999,42(8):1644-1648.
8Hayashi T, et al. Reduction of .serum interferon (IFN)-garnma concentration and lupus development in NZB×NZWF(1)mice by lactic dehydrogenase virus infection [J]. J Comp Pathol, 2001,125(4):285-291.
10Horwitz DA, Gray JD, Behrendsen SC, et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus [J].Arthritis Rheum, 1998,41(5):838-844.
二级参考文献8
1Bombardier C, Gladman DD, Urowitz MB,et al. Derivation of the SLEDAI A Disease Activity Index for Lupus Patients[J]. Arthritis Rhumatism, 1992,35:630-639.
2Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted protieins[J]. J Immunol, 1986,136:2348-2357.
3Wong CK, Ho CY,Li EK,et al. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and TH2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosous[J]. Lupus, 2001,9:589-593.
4Viallard JF, Pellegrin JL,Ranchin V,et al. Th1(IL-2,interferon-gamma(IFN-γ)) and Th2 (IL-10,IL-4)cytokine production by peripheral blood mononuclear cell (PMBC)from patients with systemic lupus erythematosous (SLE)[J].Clin Exp Immunol,1999;115;189-195.
5Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function [J]. Annu Rev Immunol, 2000,18:309-345.
6Norbiato G,Bevilacqua M, Vago T. Glucocorticoids and Th-1,Th-2type cytokines in rheumatoid arthritis, osteoarthritis, asthma, atopic dermatitis and AIDS[J]. Clin Exp Rheumatoid, 1997, 15:315-323.
7Mysliwiec J,Kretowski A,Toplskal J,et al. Serum Th1and Th2 profile cytokine level changes in patients with Graves Ophthalmopathy treatment with corticosteroids[J].Horm Metab Res, 2001,33:739-743.
8Agarwal SK,Marshall GDJR.Dexamethasone promotes type 2 cytokine production primarily through inhibition of type 1 cytokines[J]. J Interferon Cytokine Res, 2001,21:147-155.
8Fujita T, Kimura Y, Miyamoto M, et al. Induction of endogenous IFN-alpha and IFN-beta genes by a regulatory transcription factor, IRF-1. Nature, 1989, 337(6204): 270-272.
9Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev, 2000, 80(4): 1523-1631.
10Takeda K, Akira S. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev, 2000, 11(3): 199-207.
